Vudalimab for Neoplasm Metastasis
Phase-Based Progress Estimates
Effectiveness
Safety
Northwestern University, Chicago, IL
Neoplasm Metastasis+6 More
Vudalimab - DrugEligibility
18+
All Sexes
What conditions do you have?
Select
Eligibility
18+
All Sexes
What conditions do you have?
Select
Study Summary
This trial is testing an immunotherapy drug to see if it can shrink tumors in patients with certain types of thyroid cancer. Vudalimab is being used to treat Neoplasm Metastasis in a clinical trial. This is not the first time Vudalimab has been approved by the FDA, as it has been previously approved for a different condition. In this trial, no patients will receive a placebo.
Eligible Conditions
- Neoplasm Metastasis
- Thyroid Gland
Treatment Effectiveness
Effectiveness Progress
Study Objectives
1 Primary · 7 Secondary · Reporting Duration: Up to 5 years
At 16 weeks
PFS-16
Day 30
Incidence of adverse events
Up to 5 years
Clinical benefit rate
Duration of clinical benefit(DoCB)
Duration of response
Objective response rate (ORR)
Overall survival (OS)
Progression-free survival (PFS)
Trial Safety
Safety Progress
This is further along than 68% of similar trials
Trial Design
1 Treatment Group
Treatment (vudalimab)
1 of 1
Experimental Treatment
54 Total Participants · 1 Treatment Group
Primary Treatment: Vudalimab · No Placebo Group · Phase 2
Treatment (vudalimab)
Drug
Experimental Group · 1 Intervention: Vudalimab · Intervention Types: DrugTrial Logistics
Trial Timeline
Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: up to 5 years
Closest Location: Northwestern University · Chicago, IL
1993First Recorded Clinical Trial
11 TrialsResearching Neoplasm Metastasis
1052 CompletedClinical Trials
Who is running the clinical trial?
National Cancer Institute (NCI)NIH
12,937 Previous Clinical Trials
41,301,951 Total Patients Enrolled
217 Trials studying Neoplasm Metastasis
24,120 Patients Enrolled for Neoplasm Metastasis
Northwestern UniversityLead Sponsor
1,422 Previous Clinical Trials
717,631 Total Patients Enrolled
6 Trials studying Neoplasm Metastasis
2,105 Patients Enrolled for Neoplasm Metastasis
Jochen H Lorch, M.D.Principal InvestigatorNorthwestern University
Eligibility Criteria
Age 18+ · All Participants · 10 Total Inclusion Criteria
Mark “yes” if the following statements are true for you:Subjects who have received and failed, or are intolerant to, a BRAF/MEK inhibitor (e.g., dabrafenib or trametinib) must enroll in the trial.
Subjects must have a histologically confirmed diagnosis of Hurthle cell thyroid cancer (HCC)
You have Hurthle cell thyroid cancer (HCC) that is incurable, metastatic HCC.
Subjects with HCC must have previously received and failed, or be intolerant to, at least one line of primarily anti-VEGFR tyrosine kinase inhibitor therapy (e.g.
You must meet all general inclusion criteria.
Subjects with HCC must have demonstrated radiographic disease progression within =< 14 months prior to enrollment.
About The Reviewer
Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.
Top Oncology Trials
Top Clinical Trials in Cities
Relevant Clinical Trials
Unbiased Results
We believe in providing patients with all the options.Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.Back to top
Conditions
Cancer Related
Treatments